Hilana Kaafarani, MD
Nephrology · Roseville, MINPI 1174789473
Payments from drug & device makers
Across 33 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$169
- Novartis$154
- AstraZeneca$71
- Bayer$66
- Amgen$60
- Mallinckrodt Enterprises LLC$49
- plus $248 from 9 others
What the payments were for
- Food & beverage$818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 4 | $169 |
| Novartis | 6 | $154 |
| AstraZeneca | 3 | $71 |
| Bayer | 3 | $66 |
| Amgen | 3 | $60 |
| Mallinckrodt Enterprises LLC | 3 | $49 |
| Lilly USA, LLC | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $39 |
| Fresenius Kabi USA, LLC | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Abiomed | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$107
How this compares
$818 in reported general payments places this provider in the 50th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 28 | $4,248 |
| Calcium Acetate | 26 | $2,229 |
| Hydralazine Hcl | 83 | $1,223 |
| Nifedipine ErNifedipine | 32 | $1,116 |
| Metolazone | 20 | $637 |
| Tamsulosin Hcl | 18 | $467 |
| Bumetanide | 11 | $456 |
| Labetalol Hcl | 15 | $412 |
| Furosemide | 74 | $408 |
| Amlodipine Besylate | 40 | $365 |
| Losartan Potassium | 32 | $301 |
| Atorvastatin Calcium | 12 | $228 |
| Lisinopril | 20 | $193 |
| Calcitriol | 12 | $156 |
| Clonidine Hcl | 21 | $118 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Roseville
- Joel TopfRoseville$1.1M
- Heather HendersonRoseville$301K
- Keith BellovichRoseville$295K
- Mohamed El-GhorouryRoseville$11K
- Matthias KretzlerAnn Arbor$7.8M
- Fahd Al-SaghirPontiac$3.9M
- Kiran SaraiyaWarren$3.1M
- Alexander YevzlinAnn Arbor$1.3M
- Christopher ProvenzanoShelby Township$1.2M
- Jennifer OdrenSaint Clair Shores$620K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.